McKesson (MCK) Resumen de Acciones
McKesson Corporation presta servicios sanitarios en Estados Unidos y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 5/6 |
| Salud financiera | 2/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
MCK Community Fair Values
Create NarrativeSee what 104 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de McKesson Corporation
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$838.75 |
| Máximo en las últimas 52 semanas | US$999.00 |
| Mínimo de 52 semanas | US$673.38 |
| Beta | 0.31 |
| Cambio en 1 mes | 1.20% |
| Variación en 3 meses | 9.49% |
| Cambio de 1 año | 18.80% |
| Variación en 3 años | 98.12% |
| Variación en 5 años | 324.38% |
| Variación desde la OPV | 4,983.33% |
Noticias y actualizaciones recientes
Seeking Alpha • Aug 08
McKesson: Solid Q1 Earnings And Management Execution (Rating Upgrade)
Summary McKesson delivered strong Q1 results, with EPS up 20% and revenues rising 7.7% while modestly raising FY27 EPS guidance. I see GLP-1-driven momentum decelerating alongside a broader dip in the company's top-line growth profile. The Wellverse spin-off and prior divestitures are streamlining MCK, potentially justifying a premium multiple versus peers. While the valuation isn't overly attractive, management is executing well, and I'm upgrading shares to a hold rating today. Read the full article on Seeking Alpha
Actualización de narrativa • Aug 06
MCK: Biosimilar Co Manufacturing Optionality Will Drive Future Defensive Haven Appeal
McKesson's analyst fair value estimate has been raised from $941.40 to $980.80 as analysts factor in higher Street price targets and updated models that reference recent quarterly results, peer multiple moves, and shifting assumptions on long term P/E and profitability. Analyst Commentary Recent Street research on McKesson points to a mixed but generally constructive view on valuation and execution, with several firms revising price targets following quarterly updates and changes in sector assumptions.Recent updates
Seeking Alpha • Aug 08
McKesson: Solid Q1 Earnings And Management Execution (Rating Upgrade)
Summary McKesson delivered strong Q1 results, with EPS up 20% and revenues rising 7.7% while modestly raising FY27 EPS guidance. I see GLP-1-driven momentum decelerating alongside a broader dip in the company's top-line growth profile. The Wellverse spin-off and prior divestitures are streamlining MCK, potentially justifying a premium multiple versus peers. While the valuation isn't overly attractive, management is executing well, and I'm upgrading shares to a hold rating today. Read the full article on Seeking AlphaActualización de narrativa • Aug 06
MCK: Biosimilar Co Manufacturing Optionality Will Drive Future Defensive Haven Appeal
McKesson's analyst fair value estimate has been raised from $941.40 to $980.80 as analysts factor in higher Street price targets and updated models that reference recent quarterly results, peer multiple moves, and shifting assumptions on long term P/E and profitability. Analyst Commentary Recent Street research on McKesson points to a mixed but generally constructive view on valuation and execution, with several firms revising price targets following quarterly updates and changes in sector assumptions.Actualización de narrativa • Jun 25
MCK: Biosimilar Co Manufacturing Optionality Will Shape Future Haven Appeal
McKesson's analyst price target has been trimmed to $941 from $950, reflecting analysts' slightly more conservative assumptions around policy, biosimilar, and GLP-1 uncertainties, while still incorporating potential long-term benefits from areas such as biosimilar co-manufacturing. Analyst Commentary Recent Street research on McKesson points to a mixed but engaged view of the stock, with several firms revising price targets and reassessing assumptions around policy risk, biosimilars, and GLP 1 exposure.Artículo de análisis • Jun 17
McKesson (MCK) Stock Could Be 17.3% Undervalued After Loan Deal And Buybacks
McKesson (MCK) stock is in focus after a cluster of recent moves, including a US$2.25b senior secured term loan maturing in 2032, a minority sale in Medical-Surgical Solutions and ongoing share repurchases. See our latest analysis for McKesson. After a weaker quarter and a pullback that left the 90 day share price return down 14.66% and the year to date share price return down 4.62%, McKesson still has a 1 year total shareholder return of 8.87% and a very large 5 year total shareholder...Actualización de narrativa • Jun 06
MCK: Medical Surgical Spin Off And Biosimilar Manufacturing Will Shape Future Haven Appeal
McKesson's analyst price target has been trimmed by about $2 to $949.73 as analysts recalibrate their fair value and future P/E assumptions following a recent cluster of target cuts and one increase across major research firms. Analyst Commentary Bullish Takeaways Bullish analysts have recently lifted their targets in some cases, suggesting they still see upside potential relative to current execution and long term growth initiatives.Actualización de narrativa • May 13
MCK: Biosimilar Co Manufacturing Will Shape Future Healthcare Safe Haven Appeal
Analysts have trimmed the McKesson fair value estimate by about $39 to $951.73. This reflects updated views on slightly higher discount rates, a more moderate revenue growth outlook, a small shift in profit margin assumptions, and a lower future P/E multiple after a mix of recent price target increases and cuts across the Street.Artículo de análisis • May 11
McKesson Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
McKesson Corporation ( NYSE:MCK ) shareholders are probably feeling a little disappointed, since its shares fell 8.9...Actualización de narrativa • Apr 27
MCK: Biosimilar Co Manufacturing Will Shape Future Healthcare Safe Haven Appeal
McKesson's analyst price target has been trimmed slightly, with the fair value estimate edging down by about $1 to $990.87 as analysts factor in recent target cuts alongside ongoing interest in the company's biosimilar and distribution opportunities. Analyst Commentary Recent research on McKesson has centered on how much value the market is assigning to its biosimilar pipeline, distribution scale and perceived defensiveness within healthcare, with a mix of higher and lower price targets reflecting different views on execution risk and current valuation.Actualización de narrativa • Apr 10
MCK: Biosimilar Co Manufacturing Optionality Will Shape Future Safe Haven Appeal
McKesson's analyst-derived fair value estimate has been adjusted slightly lower, from about $997.67 to $991.67. Analysts are weighing recent trims to Street price targets and fresh caution around premium valuation against prior enthusiasm for biosimilar optionality and healthcare defensiveness.Actualización de narrativa • Mar 27
MCK: Biosimilar And Co Manufacturing Upside Will Shape Future Safe Haven Returns
Analysts have nudged the McKesson fair value estimate slightly higher to about $998, citing a wave of Street price target increases into the $1,040 to $1,050 range and growing focus on potential upside from biosimilars and co-manufacturing. Analyst Commentary Recent Street research around McKesson clusters around two themes: valuation and execution on new growth levers such as biosimilars and co-manufacturing.Actualización de narrativa • Mar 11
MCK: Biosimilar Optionality And Premium Safe Haven Position Will Shape Future Returns
Analysts have increased their McKesson price target from $980.40 to $995.27, citing higher Street targets that reflect new biosimilar optionality and continued interest in the stock as a perceived healthcare safe haven, even at a premium valuation. Analyst Commentary Bullish analysts are leaning into McKesson's role as a perceived healthcare safe haven and the new biosimilar angle, using these themes to justify higher valuation levels than the recent three year average.Actualización de narrativa • Feb 24
MCK: Defensive Healthcare Premium And Buybacks Will Shape Perceived Safety Trade
Analysts have raised McKesson's fair value estimate by about $14 to $980.40, as a series of higher Street price targets, including Barclays' move to $1,050, keeps the stock in focus for investors seeking perceived safety within healthcare, even as shares trade at a premium to recent averages. Analyst Commentary Recent research has centered on McKesson's valuation after a series of price target increases, including a move to US$1,050 that highlights how closely investors are watching the name as a perceived defensive healthcare holding.Actualización de narrativa • Feb 09
MCK: Refined Assumptions And Supportive Policy Backdrop Will Shape FY26 AOI
The McKesson analyst price target has been raised by about $24 to $966, with analysts pointing to updated fair value work, modest adjustments to the discount rate and growth assumptions, and slightly higher future P/E expectations as key drivers of the change. Analyst Commentary Recent Street research on McKesson clusters around higher price targets and refreshed valuation work, with analysts fine tuning assumptions on growth, discount rates and future P/E multiples.Actualización de narrativa • Jan 26
MCK: North American Pharma Momentum And Supportive Policy Backdrop Will Drive FY26 AOI
Narrative Update The analyst price target for McKesson has been raised by roughly $3 to $942.00, as analysts point to steady assumptions for revenue growth, margins and P/E, along with supportive views on North American Pharma momentum, a constructive industry demand backdrop, and the absence of new onerous proposals in recent healthcare policy commentary. Analyst Commentary Recent research on McKesson is broadly constructive, with several firms lifting their price targets and pointing to supportive sector trends and company specific drivers.Actualización de narrativa • Jan 12
MCK: North American Pharma Strength Will Support FY26 Core AOI Framework
Narrative Update: McKesson Analysts have lifted their McKesson price targets toward a range of about $900 to $1,000, citing solid North American Pharma momentum, modeled core AOI growth of around 7% for FY26, and a robust demand backdrop reflected in peers' recent results. Analyst Commentary Recent research updates reflect a more constructive stance on McKesson, with higher price targets tied to underlying business trends and peer readthroughs rather than short term trading factors.Actualización de narrativa • Dec 18
MCK: North American Pharma Momentum Will Drive Future EPS Framework Confidence
Our McKesson narrative fair value has increased modestly to approximately $939 per share from about $935, reflecting analysts' higher price targets and conviction in sustained EPS growth, improved North American Pharma momentum, and a more robust valuation framework supported by stronger industry demand trends. Analyst Commentary Street research sentiment on McKesson remains skewed positive, with a broad wave of price target increases reflecting higher conviction in the companys ability to deliver on its upgraded long term earnings framework and FY26 guidance.Actualización de narrativa • Dec 03
MCK: North American Pharma Momentum Will Drive Future Outlook Amid Policy Uncertainty
We modestly raise our McKesson fair value estimate to about $934.79 per share from roughly $934.71, reflecting analysts' higher price targets, stronger confidence in long term EPS growth, and sustained North American Pharma momentum. Analyst Commentary Street research on McKesson has turned increasingly constructive, with multiple firms lifting price targets in response to upgraded long term guidance, stronger segment momentum, and enhanced disclosure following the recent investor day.Actualización de narrativa • Nov 19
MCK: Future Execution and Pharma Trends Will Shape Outlook Amid Policy Uncertainty
McKesson's analyst price target has been raised significantly, increasing by nearly $90 per share to $934.71. Analysts cite strong momentum in North American Pharma, higher long-term EPS guidance, and robust industry trends supporting continued growth.Actualización de narrativa • Nov 05
MCK: Future Demand and Oncology Distribution Will Set the Earnings Outlook
McKesson’s analyst price target has increased from approximately $837 to $845. Analysts cite robust demand, industry-wide utilization trends, and the company’s strengthened long-term earnings outlook as key factors supporting the upward revision.Actualización de narrativa • Oct 22
Analysts Boost McKesson Outlook Amid Strong Growth Guidance and Recent Valuation Adjustments
Analysts have raised their average fair value estimate for McKesson to $836.71 from $829.57. This change is attributed to increased long-term growth guidance and improved business visibility following the company’s recent investor day.Actualización de narrativa • Oct 08
Pharmaceutical Demand And Digital Automation Will Shape Future Markets
McKesson's analyst fair value estimate has been raised from $793.21 to $829.57. This increase reflects higher price targets, driven by analysts who cite upgraded long-term growth guidance and strengthened expectations following recent investor presentations.Actualización de narrativa • Sep 24
Pharmaceutical Demand And Digital Automation Will Shape Future Markets
McKesson’s fair value saw only a marginal increase as analyst expectations for both revenue growth and net profit margin remained virtually unchanged, with the target price moving slightly from $788.57 to $793.21. What's in the News Playhouse MD™, a pediatric healthcare brand, has entered a strategic distribution alliance with McKesson Medical-Surgical, making its products available nationwide and expanding McKesson's portfolio in pediatric care.Seeking Alpha • Mar 25
McKesson: Immune To Weak Economy And Tariffs; Top Idea In 2025
Summary I maintain a 'Strong Buy' rating on McKesson with a fair value of $723 per share due to its robust oncology network and strong growth prospects. McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability, making it a reliable investment amid economic uncertainties. The company's GLP-1 and oncology franchises are key growth drivers, with GLP-1 revenue growing 45% year-over-year and oncology patient visits increasing steadily. Despite potential tariff-related risks in the biotech sector, McKesson's strong performance and strategic guidance make it a safe haven for investors in 2025. Read the full article on Seeking AlphaSeeking Alpha • Jan 21
McKesson Seems Cheap, But Risks Linger
Summary McKesson's stock appears undervalued, trading at 18 times forward earnings and free cash flow, despite recent price increases and solid growth prospects in oncology and GLP-1 medications. Quarterly results show mixed performance, with revenue up 21.3% YoY but operating income and EPS down; adjusted EPS grew 13.5% YoY. Risks include political pressures on drug pricing, competition from vertically integrated healthcare providers like CVS and Amazon, and potential recession impacts. Despite bullish arguments and recession resilience, I rate McKesson as a 'Hold' due to high recession risk and a cautious market outlook. Read the full article on Seeking AlphaSeeking Alpha • Nov 09
McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network
Summary I reiterate a 'Strong Buy' on McKesson, driven by growth from GLP-1 medications and a robust oncology network business, with a fair value of $696 per share. McKesson's acquisition of a 70% interest in Florida Cancer Specialists enhances its oncology network, expanding to 3,300 providers across 31 states. Strong Q2 results with 21% revenue growth and raised EPS guidance to $32.40-$33.00, driven by specialty distribution and retail national account customers. Future growth driven by GLP-1 medications, oncology network expansion, and margin improvements, despite weak growth in Medical surgical solutions post-Covid. Read the full article on Seeking AlphaSeeking Alpha • Oct 09
McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff
Summary Healthcare is a great defensive sector that has lower amounts of cyclicality than others that depend on the booming economy. With the stock currently down -21.44% off of its all-time high, the stock is giving investors a nice entry point as it reverts to the mean S&P500 returns. The company was the highest-scoring large cap on the most recent Magic Formula screen for October 2024. The Healthcare distribution sub-sector provides exposure to big Pharma without the patent cliffs. Read the full article on Seeking AlphaSeeking Alpha • Sep 10
McKesson: The Correction Is Not Over
Summary McKesson declined about 20% in the last few weeks and sentiment suddenly turned. Of course, McKesson is performing hand-in-hand with the overall market and we can expect that McKesson will continue to decline - similar to the overall market. On the other hand, we can argue that McKesson is already undervalued a bit, but I still think the stock will continue to decline further due to the overall sentiment. Read the full article on Seeking AlphaRentabilidad de los accionistas
| MCK | US Healthcare | Mercado US | |
|---|---|---|---|
| 7D | -2.1% | -1.5% | -2.1% |
| 1Y | 18.8% | 23.0% | 18.8% |
Rentabilidad vs. Industria: Los resultados de MCK fueron inferiores a los de la industria US Healthcare, que obtuvo un rendimiento del 23% el año pasado.
Rentabilidad vs. Mercado: MCK igualó el mercado US, que obtuvo un rendimiento del 18.8% el año pasado.
Volatilidad de los precios
| MCK volatility | |
|---|---|
| MCK Average Weekly Movement | 4.4% |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: MCK no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de MCK (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1833 | 42,300 | Brian Tyler | www.mckesson.com |
McKesson Corporation presta servicios sanitarios en Estados Unidos y a escala internacional. Opera a través de cuatro segmentos: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions y Medical-Surgical Solutions. La empresa distribuye medicamentos de marca, genéricos, especiales, biosimilares y de venta libre, así como otros productos relacionados con la atención sanitaria; suministra productos a farmacias minoristas, hospitales, centros de atención a largo plazo, clínicas e instituciones; y presta servicios de logística y distribución a fabricantes.
Resumen de fundamentos de McKesson Corporation
| Estadísticas fundamentales de MCK | |
|---|---|
| Capitalización bursátil | US$99.53b |
| Beneficios(TTM) | US$4.59b |
| Ingresos (TTM) | US$410.98b |
21.3x
Ratio precio-beneficio (PE)0.2x
Ratio precio-ventas (PS)¿Está MCK sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MCK | |
|---|---|
| Ingresos | US$410.98b |
| Coste de los ingresos | US$396.05b |
| Beneficio bruto | US$14.93b |
| Otros gastos | US$10.34b |
| Beneficios | US$4.59b |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 39.39 |
| Margen bruto | 3.63% |
| Margen de beneficio neto | 1.12% |
| Ratio deuda/patrimonio | -742.5% |
¿Cómo se ha desempeñado MCK a largo plazo?
Ver rendimiento histórico y comparativaDividendos
0.4%
Rentabilidad actual por dividendo9%
Ratio de pagos¿Paga MCK dividendos fiables?
Ver historial de dividendos e índices de referencia de MCK| fechas de dividendos de McKesson | |
|---|---|
| Fecha ex dividendo | Sep 01 2026 |
| Fecha de pago de dividendos | Oct 01 2026 |
| Días hasta ex dividendo | 10 days |
| Días hasta la fecha de pago de dividendos | 40 days |
¿Paga MCK dividendos fiables?
Ver historial de dividendos e índices de referencia de MCKAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/20 12:25 |
| Precio de las acciones al final del día | 2026/08/20 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
McKesson Corporation está cubierta por 33 analistas. 16 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| David Toung | Argus Research Company |
| Eric Coldwell | Baird |
| Glen Santangelo | Barclays |